Studies comparing lung cancer patients treated with immune checkpoint inhibitors revealed that those with low tumor cell αv expression exhibited better prognosis and higher intratumoral density of CD8+CD103+ resident memory T cells (Trm) (98). This evidence concerns the gene CD8A and neoplasm.